Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs


Yang W., ERSOY C., Wang G., Ye S., Liu J., Miao H., ...More

DIABETES RESEARCH AND CLINICAL PRACTICE, vol.150, pp.158-166, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 150
  • Publication Date: 2019
  • Doi Number: 10.1016/j.diabres.2019.02.023
  • Journal Name: DIABETES RESEARCH AND CLINICAL PRACTICE
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.158-166

Abstract

Aims: To compare the efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) administered three times daily (TID) vs. twice daily (BID), plus metformin, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin +/- 1 oral antidiabetic drug (OAD).